CompLEEment-1 Canadian Correlative Sub-Study
LEEOMIC: CompLEEment-1 Canadian Correlative Sub-Study Comprehensive Proteomic Analysis Towards Discovery of Predictive Patterns of Protein Expression to Ribociclib Sensitivity and Resistance
ClinicalTrials.gov Identifier: NCT03613220
Novartis Reference Number: CLEE011ACA02
Last Update: May 19, 2020
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Study Description
Collection of tumor and blood samples from subjects enrolled in the main study (LEE011A2404) will undergo proteomic and ctDNA analysis respectively to better understand mechanisms of response and resistance to ribociclib in combination with letrozole therapy.
Interventions
Eligibility Criteria
Inclusion Criteria:
must have been eligible and participated in the main LEE011A2404 study
must provide consent to collect samples
Exclusion Criteria:
if consent not given to collect samples
Patients without either archival tumor tissue block or slides accessible
Study Locations
Contacts
Have a question?
Call 1-888-669-6682 or email [email protected]